Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutationSusan M. Domchek, Robert H. Vonderheide, Andrew Hendifar et al.|Cancer Research|2015Cited by 4